These findings can be used as a model to study and therapeutically target the truncated O-glycan-containing MUC16/integrin/ILK/FAK-signaling cascade to develop treatments against metastatic pancreatic cancer (Figure 6). Here, ILK is linked to pancreatic neoplasm.